Recurrent Melanoma Completed Phase 2 Trials for Bortezomib (DB00188)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00024011PS-341 in Treating Patients With Metastatic Malignant MelanomaTreatment
NCT00288041Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic MelanomaTreatment